Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
Following a 12-week exercise to gather further information on the risks and benefits of the painkiller co-proxamol, UK Ministers decided in January 2005 to accept the advice of the Committee on Safety of Medicines (CSM) that co-proxamol should be withdrawn from the market over a period of time. The following documents have been issued:
›
Letter to healthcare professionals - 31 January 2005
›
Questions and answers - July 2005
›
Outcome of the public request for information on the risks and benefits of co-proxamol - January 2005
›
Advice on analgesic options in treatment of mild to moderate pain in adults - January 2005
›
Advice from the CSM Expert Working Group on analgesic options in treatment of mild to moderate pain - January 2005
›
Withdrawal of co-proxamol: Reminder to prescribers - March 2006
›
Position on the sale and supply of co-proxamol following cancellation of the marketing authorisations (MAs) at the end 2007 - 14 December 2007
›
European Medicines Agency (EMEA) recommends withdrawal of dextropropoxyphene-containing medicines (including co-proxamol) - 25 June 2009
